Trump wins U.S. election | Expert analysis on e-cigarette policy direction under the next administration

Nov.06.2024
Trump wins U.S. election | Expert analysis on e-cigarette policy direction under the next administration
Tom Beaudet, CEO of U.S. compliance firm Accorto, reviewed the effectiveness of past bipartisan policies and predicts that the FDA will improve its review process, allowing e-cigarette products to gain market approval more quickly in the future.

The results of the 2024 U.S. presidential election have been revealed, with Donald Trump elected as the new president. As the largest e-cigarette market in the world, the direction and regulatory policies of the U.S. market have significant global implications. How the new administration will regulate e-cigarettes and the future of the U.S. e-cigarette market are questions drawing global industry attention. As a leading global vaping technology media and think tank, 2Firsts quickly connected with U.S. compliance experts to provide the most authoritative analysis.

 

Tom Beaudet, CEO of U.S. compliance firm Accorto, shared with 2Firsts his thoughts on the regulatory approaches and actions of both the Trump administration and the current Democratic government on e-cigarettes. He emphasized that, during the current administration's four years, only 9 harm-reduction product applications were approved, despite millions of applications being submitted. He predicts that under the next administration, the FDA may gradually establish a clearer market entry pathway, helping companies that submit complete scientific data gain market access more quickly.

 

Trump wins U.S. election | Expert analysis on e-cigarette policy direction under the next administration
Accorto CEO Tom Beaudet | Image source: 2Firsts

 

Read the full perspective from Tom Beaudet:

 

  • Several weeks ago, ex President Donald Trump made the statement that he saved flavored vapes in 2020 and that, if he is elected again, he will save flavors again. However, it must be remembered that flavored closed pod systems were banned during the Trump presidency.

 

  • During the past 4 years, FDA has only approved 9 new harm reduction products, although applications have been submitted for millions of new products.  Although the vast majority of those applications were not complete with the scientific data needed for substantive review by the CTP Office of Science, several companies did submit high quality applications and are still awaiting a final decision.  Many question why we should expect anything different under another Democratic Party administration.

 

  • There is hope, regardless of who walks away victorious on November 5.  The US VTA, led by their president Tony Abud, has been aggressively working to educate members of Congress from both parties about the life saving potential of Nicotine Harm Reduction products and the importance of making changes at FDA to repair the currently broken review process.  Regardless of who wins tomorrow, we should expect to see improvements in the PMTA review process where applications who spend the money and time to submit high quality applications have a known and proven pathway to a Market Granted Order.  As more products are approved and we develop a pool of predicate products to reference, the known pathway to success will be come more and more established.

 


 

2Firsts will continue to bring the latest reports and interpretations on U.S. e-cigarette policies.

 

Disclaimer: This article represents only the views of the expert.

Product | 2Firsts Exclusive: Breaking Down Pachamama 25K, CHUC’s First U.S.-Made Factory Product
Product | 2Firsts Exclusive: Breaking Down Pachamama 25K, CHUC’s First U.S.-Made Factory Product
U.S. e-cigarette company Charlie’s has brought its first domestic manufacturing facility online, launching the disposable Pachamama 25K, which will initially roll out to 300 retail stores in Texas. The device features a 20 ml e-liquid capacity with 5% nicotine, three power modes and a built-in 1000 mAh battery, and is advertised to deliver up to 25,000 puffs.
Dec.02 by 2FIRSTS.ai
UK Launches Call for Evidence to Shape New Tobacco and Vapes Regulations
UK Launches Call for Evidence to Shape New Tobacco and Vapes Regulations
The UK's Department of Health and Social Care (DHSC) has launched an eight-week comprehensive call for evidence to inform new regulations under the forthcoming Tobacco and Vapes Bill, with a deadline of December 3, 2025. The initiative aims to systematically gather evidence on vape flavors, ingredients, nicotine levels, and product design, as well as proposals for an omnichannel retail licensing scheme for tobacco and vapes and a new product registration system.
Nov.04 by 2FIRSTS.ai
Altria CEO Billy Gifford to Retire; Sal Mancuso Named Successor
Altria CEO Billy Gifford to Retire; Sal Mancuso Named Successor
Altria Group, Inc. (NYSE: MO) announced that CEO Billy Gifford will retire at the conclusion of the 2026 Annual Meeting of Shareholders on May 14, 2026, after more than 30 years with the company. The Board of Directors has elected Salvatore (Sal) Mancuso, Altria’s current Executive Vice President and CFO, to succeed him as CEO.
Dec.12 by 2FIRSTS.ai
Morocco Aligns Cigarette Pricing Structure with New 2026 Tax Adjustment
Morocco Aligns Cigarette Pricing Structure with New 2026 Tax Adjustment
Morocco will raise retail cigarette prices by 1–2 dirhams (≈ US$ 0.10–0.20) per pack starting January 1, 2026, as part of the final phase of its tobacco tax reform. The adjustment mainly affects value-category cigarette brands; premiums remain largely unchanged.
Dec.01
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21
BAT Pauses U.S. Launch of Unlicensed Vuse One Vape amid FDA Crackdown — Reuters
BAT Pauses U.S. Launch of Unlicensed Vuse One Vape amid FDA Crackdown — Reuters
British American Tobacco has paused the U.S. pilot launch of its unlicensed Vuse One vape amid intensified FDA enforcement.
Oct.28 by 2FIRSTS.ai